PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
31851841-0	2020	Taraxasterol protects hippocampal neurons from oxygen-glucose deprivation-induced injury through activation of Nrf2 signalling pathway.	taraxasterol	0-12	NFE2 like bZIP transcription factor 2	Homo sapiens	111-115
31851841-12	2020	Taraxasterol resulted in a significant decrease in caspase-3 activity and bcl-2 expression, as well as increase in bax expression.	taraxasterol	0-12	caspase 3	Homo sapiens	51-60
31851841-12	2020	Taraxasterol resulted in a significant decrease in caspase-3 activity and bcl-2 expression, as well as increase in bax expression.	taraxasterol	0-12	BCL2 apoptosis regulator	Homo sapiens	74-79
31851841-12	2020	Taraxasterol resulted in a significant decrease in caspase-3 activity and bcl-2 expression, as well as increase in bax expression.	taraxasterol	0-12	BCL2 associated X, apoptosis regulator	Homo sapiens	115-118
31851841-13	2020	Furthermore, taraxasterol induced the Nrf2 nuclear accumulation and expressions of HO-1, NQO-1 and GPx-3 in OGD/R-induced hippocampal neurons.	taraxasterol	13-25	NFE2 like bZIP transcription factor 2	Homo sapiens	38-42
31851841-13	2020	Furthermore, taraxasterol induced the Nrf2 nuclear accumulation and expressions of HO-1, NQO-1 and GPx-3 in OGD/R-induced hippocampal neurons.	taraxasterol	13-25	heme oxygenase 1	Homo sapiens	83-87
31851841-13	2020	Furthermore, taraxasterol induced the Nrf2 nuclear accumulation and expressions of HO-1, NQO-1 and GPx-3 in OGD/R-induced hippocampal neurons.	taraxasterol	13-25	NAD(P)H quinone dehydrogenase 1	Homo sapiens	89-94
31851841-13	2020	Furthermore, taraxasterol induced the Nrf2 nuclear accumulation and expressions of HO-1, NQO-1 and GPx-3 in OGD/R-induced hippocampal neurons.	taraxasterol	13-25	glutathione peroxidase 3	Homo sapiens	99-104
31851841-14	2020	Notably, inhibition of Nrf2 signalling reversed the protective effects of taraxasterol on OGD/R-induced hippocampal neurons injury.	taraxasterol	74-86	NFE2 like bZIP transcription factor 2	Homo sapiens	23-27
31851841-15	2020	In conclusion, these findings indicated that taraxasterol protected hippocampal neurons from OGD/R-induced oxidative stress and cell apoptosis via regulating the Nrf2 signalling pathway.	taraxasterol	45-57	NFE2 like bZIP transcription factor 2	Homo sapiens	162-166
33035580-0	2020	Effects of taraxasterol against ethanol and high-fat diet-induced liver injury by regulating TLR4/MyD88/NF-kappaB and Nrf2/HO-1 signaling pathways.	taraxasterol	11-23	toll like receptor 4	Homo sapiens	93-97
33183976-7	2020	Treatment with taraxasterol attenuated the following in a dose-dependent manner: tubular damage; infiltration of F4/80-positive macrophages; renal interstitial fibrosis; myeloperoxidase (MPO) activity; and expression of the inflammatory cytokines tumour necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), and monocyte chemoattractant protein-1 (MCP-1).	taraxasterol	15-27	adhesion G protein-coupled receptor E1	Mus musculus	113-118
33183976-7	2020	Treatment with taraxasterol attenuated the following in a dose-dependent manner: tubular damage; infiltration of F4/80-positive macrophages; renal interstitial fibrosis; myeloperoxidase (MPO) activity; and expression of the inflammatory cytokines tumour necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), and monocyte chemoattractant protein-1 (MCP-1).	taraxasterol	15-27	myeloperoxidase	Mus musculus	170-185
33183976-7	2020	Treatment with taraxasterol attenuated the following in a dose-dependent manner: tubular damage; infiltration of F4/80-positive macrophages; renal interstitial fibrosis; myeloperoxidase (MPO) activity; and expression of the inflammatory cytokines tumour necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), and monocyte chemoattractant protein-1 (MCP-1).	taraxasterol	15-27	myeloperoxidase	Mus musculus	187-190
33183976-7	2020	Treatment with taraxasterol attenuated the following in a dose-dependent manner: tubular damage; infiltration of F4/80-positive macrophages; renal interstitial fibrosis; myeloperoxidase (MPO) activity; and expression of the inflammatory cytokines tumour necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), and monocyte chemoattractant protein-1 (MCP-1).	taraxasterol	15-27	tumor necrosis factor	Mus musculus	277-286
33183976-7	2020	Treatment with taraxasterol attenuated the following in a dose-dependent manner: tubular damage; infiltration of F4/80-positive macrophages; renal interstitial fibrosis; myeloperoxidase (MPO) activity; and expression of the inflammatory cytokines tumour necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), and monocyte chemoattractant protein-1 (MCP-1).	taraxasterol	15-27	interleukin 1 beta	Mus musculus	289-306
33183976-7	2020	Treatment with taraxasterol attenuated the following in a dose-dependent manner: tubular damage; infiltration of F4/80-positive macrophages; renal interstitial fibrosis; myeloperoxidase (MPO) activity; and expression of the inflammatory cytokines tumour necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), and monocyte chemoattractant protein-1 (MCP-1).	taraxasterol	15-27	interleukin 1 alpha	Mus musculus	308-316
33183976-7	2020	Treatment with taraxasterol attenuated the following in a dose-dependent manner: tubular damage; infiltration of F4/80-positive macrophages; renal interstitial fibrosis; myeloperoxidase (MPO) activity; and expression of the inflammatory cytokines tumour necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), and monocyte chemoattractant protein-1 (MCP-1).	taraxasterol	15-27	chemokine (C-C motif) ligand 2	Mus musculus	323-357
33183976-7	2020	Treatment with taraxasterol attenuated the following in a dose-dependent manner: tubular damage; infiltration of F4/80-positive macrophages; renal interstitial fibrosis; myeloperoxidase (MPO) activity; and expression of the inflammatory cytokines tumour necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), and monocyte chemoattractant protein-1 (MCP-1).	taraxasterol	15-27	chemokine (C-C motif) ligand 2	Mus musculus	359-364
33183976-8	2020	Moreover, taraxasterol treatment remarkably ameliorated apoptosis in the kidney by decreasing Bax expression and conserving Bcl2.	taraxasterol	10-22	BCL2-associated X protein	Mus musculus	94-97
33183976-8	2020	Moreover, taraxasterol treatment remarkably ameliorated apoptosis in the kidney by decreasing Bax expression and conserving Bcl2.	taraxasterol	10-22	B cell leukemia/lymphoma 2	Mus musculus	124-128
33183976-10	2020	Furthermore, taraxasterol suppressed phosphorylation of extracellular signal-regulated kinase (ERK) and c-Jun NH2-terminal kinase (JNK) of the mitogen-activated protein kinase (MAPK) signaling pathways in vivo and in vitro.	taraxasterol	13-25	mitogen-activated protein kinase 1	Mus musculus	56-93
33183976-10	2020	Furthermore, taraxasterol suppressed phosphorylation of extracellular signal-regulated kinase (ERK) and c-Jun NH2-terminal kinase (JNK) of the mitogen-activated protein kinase (MAPK) signaling pathways in vivo and in vitro.	taraxasterol	13-25	mitogen-activated protein kinase 1	Mus musculus	95-98
33183976-10	2020	Furthermore, taraxasterol suppressed phosphorylation of extracellular signal-regulated kinase (ERK) and c-Jun NH2-terminal kinase (JNK) of the mitogen-activated protein kinase (MAPK) signaling pathways in vivo and in vitro.	taraxasterol	13-25	mitogen-activated protein kinase 8	Mus musculus	104-129
33183976-10	2020	Furthermore, taraxasterol suppressed phosphorylation of extracellular signal-regulated kinase (ERK) and c-Jun NH2-terminal kinase (JNK) of the mitogen-activated protein kinase (MAPK) signaling pathways in vivo and in vitro.	taraxasterol	13-25	mitogen-activated protein kinase 8	Mus musculus	131-134
33035580-5	2020	More specifically, ethanol-induced TLR-4 and MyD88 inflammatory response were down-regulated, when treated with TAR.	taraxasterol	112-115	toll like receptor 4	Homo sapiens	35-40
33035580-5	2020	More specifically, ethanol-induced TLR-4 and MyD88 inflammatory response were down-regulated, when treated with TAR.	taraxasterol	112-115	MYD88 innate immune signal transduction adaptor	Homo sapiens	45-50
33035580-0	2020	Effects of taraxasterol against ethanol and high-fat diet-induced liver injury by regulating TLR4/MyD88/NF-kappaB and Nrf2/HO-1 signaling pathways.	taraxasterol	11-23	MYD88 innate immune signal transduction adaptor	Homo sapiens	98-103
33035580-0	2020	Effects of taraxasterol against ethanol and high-fat diet-induced liver injury by regulating TLR4/MyD88/NF-kappaB and Nrf2/HO-1 signaling pathways.	taraxasterol	11-23	nuclear factor kappa B subunit 1	Homo sapiens	104-113
33035580-0	2020	Effects of taraxasterol against ethanol and high-fat diet-induced liver injury by regulating TLR4/MyD88/NF-kappaB and Nrf2/HO-1 signaling pathways.	taraxasterol	11-23	NFE2 like bZIP transcription factor 2	Homo sapiens	118-122
33035580-0	2020	Effects of taraxasterol against ethanol and high-fat diet-induced liver injury by regulating TLR4/MyD88/NF-kappaB and Nrf2/HO-1 signaling pathways.	taraxasterol	11-23	heme oxygenase 1	Homo sapiens	123-127
32647534-14	2020	The present study revealed that dandelion and its component taraxasterol could inhibit HBV and may be a potential anti-HBV drug, whose potential targets were the host factors PTBP1 and SIRT1.	taraxasterol	60-72	polypyrimidine tract binding protein 1	Homo sapiens	175-180
32647534-14	2020	The present study revealed that dandelion and its component taraxasterol could inhibit HBV and may be a potential anti-HBV drug, whose potential targets were the host factors PTBP1 and SIRT1.	taraxasterol	60-72	sirtuin 1	Homo sapiens	185-190
31571510-5	2019	Taraxasterol also significantly inhibited the release of pro-inflammatory cytokines tumour necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), IL-1beta, interferon-gamma (IFN-gamma) and IL-4.	taraxasterol	0-12	tumor necrosis factor	Mus musculus	114-123
32701378-8	2020	Further investigations showed that, TAX administration repressed xenograft tumor growth and decreased Ki-67 levels, followed by the downregulation of EGFR and AKT1 expression in xenograft tumor tissues as compared with the untreated group.	taraxasterol	36-39	epidermal growth factor receptor	Homo sapiens	150-154
32701378-8	2020	Further investigations showed that, TAX administration repressed xenograft tumor growth and decreased Ki-67 levels, followed by the downregulation of EGFR and AKT1 expression in xenograft tumor tissues as compared with the untreated group.	taraxasterol	36-39	AKT serine/threonine kinase 1	Homo sapiens	159-163
32701378-9	2020	Our findings demonstrated that TAX inhibited the growth of GC by inhibition of EGFR/AKT1 signaling and might provide a novel therapeutic strategy for treatment of GC.	taraxasterol	31-34	epidermal growth factor receptor	Homo sapiens	79-83
32701378-9	2020	Our findings demonstrated that TAX inhibited the growth of GC by inhibition of EGFR/AKT1 signaling and might provide a novel therapeutic strategy for treatment of GC.	taraxasterol	31-34	AKT serine/threonine kinase 1	Homo sapiens	84-88
31571510-0	2019	Taraxasterol from Taraxacum prevents concanavalin A-induced acute hepatic injury in mice via modulating TLRs/NF-kappaB and Bax/Bc1-2 signalling pathways.	taraxasterol	0-12	BCL2-associated X protein	Mus musculus	123-126
31571510-0	2019	Taraxasterol from Taraxacum prevents concanavalin A-induced acute hepatic injury in mice via modulating TLRs/NF-kappaB and Bax/Bc1-2 signalling pathways.	taraxasterol	0-12	brain cytoplasmic RNA 1	Mus musculus	127-130
31571510-4	2019	It was found that treatment with taraxasterol significantly decreased the Con A-induced increase of liver index, serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and hepatic malondialdehyde (MDA) levels, and increased the Con A-induced decrease of hepatic glutathione (GSH) and superoxide dismutase (SOD) production.	taraxasterol	33-45	glutamic pyruvic transaminase, soluble	Mus musculus	119-143
31571510-4	2019	It was found that treatment with taraxasterol significantly decreased the Con A-induced increase of liver index, serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and hepatic malondialdehyde (MDA) levels, and increased the Con A-induced decrease of hepatic glutathione (GSH) and superoxide dismutase (SOD) production.	taraxasterol	33-45	glutamic pyruvic transaminase, soluble	Mus musculus	145-148
31571510-4	2019	It was found that treatment with taraxasterol significantly decreased the Con A-induced increase of liver index, serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and hepatic malondialdehyde (MDA) levels, and increased the Con A-induced decrease of hepatic glutathione (GSH) and superoxide dismutase (SOD) production.	taraxasterol	33-45	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	154-180
31571510-4	2019	It was found that treatment with taraxasterol significantly decreased the Con A-induced increase of liver index, serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and hepatic malondialdehyde (MDA) levels, and increased the Con A-induced decrease of hepatic glutathione (GSH) and superoxide dismutase (SOD) production.	taraxasterol	33-45	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	182-185
31571510-5	2019	Taraxasterol also significantly inhibited the release of pro-inflammatory cytokines tumour necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), IL-1beta, interferon-gamma (IFN-gamma) and IL-4.	taraxasterol	0-12	interleukin 6	Mus musculus	126-139
31571510-5	2019	Taraxasterol also significantly inhibited the release of pro-inflammatory cytokines tumour necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), IL-1beta, interferon-gamma (IFN-gamma) and IL-4.	taraxasterol	0-12	interleukin 6	Mus musculus	141-145
31571510-5	2019	Taraxasterol also significantly inhibited the release of pro-inflammatory cytokines tumour necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), IL-1beta, interferon-gamma (IFN-gamma) and IL-4.	taraxasterol	0-12	interleukin 1 beta	Mus musculus	148-156
31571510-5	2019	Taraxasterol also significantly inhibited the release of pro-inflammatory cytokines tumour necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), IL-1beta, interferon-gamma (IFN-gamma) and IL-4.	taraxasterol	0-12	interferon gamma	Mus musculus	158-174
31571510-5	2019	Taraxasterol also significantly inhibited the release of pro-inflammatory cytokines tumour necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), IL-1beta, interferon-gamma (IFN-gamma) and IL-4.	taraxasterol	0-12	interferon gamma	Mus musculus	176-185
31571510-5	2019	Taraxasterol also significantly inhibited the release of pro-inflammatory cytokines tumour necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), IL-1beta, interferon-gamma (IFN-gamma) and IL-4.	taraxasterol	0-12	interleukin 4	Mus musculus	191-195
31571510-7	2019	Furthermore, taraxasterol dramatically down-regulated the expressions of T toll-like receptor (TLR2), TLR4 and nuclear factor-kappaappaB (NF-kappaB) p65, and decreased the expression ratio of Bax/Bc1-2 in hepatic tissues.	taraxasterol	13-25	toll-like receptor 2	Mus musculus	95-99
31571510-7	2019	Furthermore, taraxasterol dramatically down-regulated the expressions of T toll-like receptor (TLR2), TLR4 and nuclear factor-kappaappaB (NF-kappaB) p65, and decreased the expression ratio of Bax/Bc1-2 in hepatic tissues.	taraxasterol	13-25	toll-like receptor 4	Mus musculus	102-136
31571510-7	2019	Furthermore, taraxasterol dramatically down-regulated the expressions of T toll-like receptor (TLR2), TLR4 and nuclear factor-kappaappaB (NF-kappaB) p65, and decreased the expression ratio of Bax/Bc1-2 in hepatic tissues.	taraxasterol	13-25	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	149-152
31571510-7	2019	Furthermore, taraxasterol dramatically down-regulated the expressions of T toll-like receptor (TLR2), TLR4 and nuclear factor-kappaappaB (NF-kappaB) p65, and decreased the expression ratio of Bax/Bc1-2 in hepatic tissues.	taraxasterol	13-25	BCL2-associated X protein	Mus musculus	192-195
31571510-7	2019	Furthermore, taraxasterol dramatically down-regulated the expressions of T toll-like receptor (TLR2), TLR4 and nuclear factor-kappaappaB (NF-kappaB) p65, and decreased the expression ratio of Bax/Bc1-2 in hepatic tissues.	taraxasterol	13-25	brain cytoplasmic RNA 1	Mus musculus	196-201
31571510-8	2019	These findings suggest that taraxasterol prevents Con A-induced acute hepatic injury in mice by inhibiting TLRs/NF-kappaB inflammatory signalling pathway and promoting Bax/Bc1-2 anti-apoptotic signalling pathway.	taraxasterol	28-40	BCL2-associated X protein	Mus musculus	168-171
31571510-8	2019	These findings suggest that taraxasterol prevents Con A-induced acute hepatic injury in mice by inhibiting TLRs/NF-kappaB inflammatory signalling pathway and promoting Bax/Bc1-2 anti-apoptotic signalling pathway.	taraxasterol	28-40	brain cytoplasmic RNA 1	Mus musculus	172-177
30927736-5	2019	RESULTS: 14 collective targets of taraxasterol and acute colitis were identified by a network pharmacology analysis, including PPARG, JAK2, MMP3, NR1I2 and PTPN11.	taraxasterol	34-46	peroxisome proliferator activated receptor gamma	Mus musculus	127-132
31410133-8	2019	The results from the MTT assay identified the optimal concentration of LPS and taraxasterol, and ELISA results demonstrated that taraxasterol treatment decreased the expression levels of IL-6 and TNF-alpha in vitro and in vivo, in a dose-dependent manner.	taraxasterol	129-141	interleukin 6	Mus musculus	187-191
31410133-8	2019	The results from the MTT assay identified the optimal concentration of LPS and taraxasterol, and ELISA results demonstrated that taraxasterol treatment decreased the expression levels of IL-6 and TNF-alpha in vitro and in vivo, in a dose-dependent manner.	taraxasterol	129-141	tumor necrosis factor	Mus musculus	196-205
31410133-9	2019	Taraxasterol treatment inhibited apoptosis, and reduced the protein levels of p53, Bcl-2 associated X (BAX) and caspase-3.	taraxasterol	0-12	transformation related protein 53, pseudogene	Mus musculus	78-81
31410133-9	2019	Taraxasterol treatment inhibited apoptosis, and reduced the protein levels of p53, Bcl-2 associated X (BAX) and caspase-3.	taraxasterol	0-12	BCL2-associated X protein	Mus musculus	83-101
31410133-9	2019	Taraxasterol treatment inhibited apoptosis, and reduced the protein levels of p53, Bcl-2 associated X (BAX) and caspase-3.	taraxasterol	0-12	BCL2-associated X protein	Mus musculus	103-106
31410133-9	2019	Taraxasterol treatment inhibited apoptosis, and reduced the protein levels of p53, Bcl-2 associated X (BAX) and caspase-3.	taraxasterol	0-12	caspase 3	Mus musculus	112-121
30927736-5	2019	RESULTS: 14 collective targets of taraxasterol and acute colitis were identified by a network pharmacology analysis, including PPARG, JAK2, MMP3, NR1I2 and PTPN11.	taraxasterol	34-46	Janus kinase 2	Mus musculus	134-138
30927736-5	2019	RESULTS: 14 collective targets of taraxasterol and acute colitis were identified by a network pharmacology analysis, including PPARG, JAK2, MMP3, NR1I2 and PTPN11.	taraxasterol	34-46	matrix metallopeptidase 3	Mus musculus	140-144
30927736-5	2019	RESULTS: 14 collective targets of taraxasterol and acute colitis were identified by a network pharmacology analysis, including PPARG, JAK2, MMP3, NR1I2 and PTPN11.	taraxasterol	34-46	nuclear receptor subfamily 1, group I, member 2	Mus musculus	146-151
30927736-5	2019	RESULTS: 14 collective targets of taraxasterol and acute colitis were identified by a network pharmacology analysis, including PPARG, JAK2, MMP3, NR1I2 and PTPN11.	taraxasterol	34-46	protein tyrosine phosphatase, non-receptor type 11	Mus musculus	156-162
30927736-6	2019	Further investigations in an AEC model showed that, taraxasterol alleviated the unfavorable clinical symptoms and attenuated the intestinal inflammation response by reducing the cytokines TNF-alpha, IL-1beta and IL-6 levels.	taraxasterol	52-64	tumor necrosis factor	Mus musculus	188-197
30927736-6	2019	Further investigations in an AEC model showed that, taraxasterol alleviated the unfavorable clinical symptoms and attenuated the intestinal inflammation response by reducing the cytokines TNF-alpha, IL-1beta and IL-6 levels.	taraxasterol	52-64	interleukin 1 alpha	Mus musculus	199-207
30927736-6	2019	Further investigations in an AEC model showed that, taraxasterol alleviated the unfavorable clinical symptoms and attenuated the intestinal inflammation response by reducing the cytokines TNF-alpha, IL-1beta and IL-6 levels.	taraxasterol	52-64	interleukin 6	Mus musculus	212-216
30927736-7	2019	qRT-PCR and IHC analysis evidenced that, taraxasterol decreased MMP3 expression levels, but increased PPARG expression levels in AEC models as compared with the DSS group.	taraxasterol	41-53	matrix metallopeptidase 3	Mus musculus	64-68
30927736-7	2019	qRT-PCR and IHC analysis evidenced that, taraxasterol decreased MMP3 expression levels, but increased PPARG expression levels in AEC models as compared with the DSS group.	taraxasterol	41-53	peroxisome proliferator activated receptor gamma	Mus musculus	102-107
30927736-8	2019	CONCLUSIONS: Our findings demonstrated that taraxasterol improved DSS-induced AEC through regulating MMP3 and PPARG expression, providing a new insight into the potential therapeutic strategies for acute colitis.	taraxasterol	44-56	matrix metallopeptidase 3	Mus musculus	101-105
30927736-8	2019	CONCLUSIONS: Our findings demonstrated that taraxasterol improved DSS-induced AEC through regulating MMP3 and PPARG expression, providing a new insight into the potential therapeutic strategies for acute colitis.	taraxasterol	44-56	peroxisome proliferator activated receptor gamma	Mus musculus	110-115
29951871-5	2018	The results showed that taraxasterol not only reduced the production of TNF-alpha, IL-8, PGE2, and NO induced by LPS, but also reduced the expression of iNOS and COX-2.	taraxasterol	24-36	tumor necrosis factor	Homo sapiens	72-81
30851708-0	2019	Taraxasterol suppresses inflammation in IL-1beta-induced rheumatoid arthritis fibroblast-like synoviocytes and rheumatoid arthritis progression in mice.	taraxasterol	0-12	interleukin 1 beta	Mus musculus	40-48
29951871-5	2018	The results showed that taraxasterol not only reduced the production of TNF-alpha, IL-8, PGE2, and NO induced by LPS, but also reduced the expression of iNOS and COX-2.	taraxasterol	24-36	C-X-C motif chemokine ligand 8	Homo sapiens	83-87
29951871-5	2018	The results showed that taraxasterol not only reduced the production of TNF-alpha, IL-8, PGE2, and NO induced by LPS, but also reduced the expression of iNOS and COX-2.	taraxasterol	24-36	nitric oxide synthase 2	Homo sapiens	153-157
29951871-5	2018	The results showed that taraxasterol not only reduced the production of TNF-alpha, IL-8, PGE2, and NO induced by LPS, but also reduced the expression of iNOS and COX-2.	taraxasterol	24-36	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	162-167
29951871-6	2018	Taraxasterol also suppressed LPS-induced NF-kappaB activation and VCAM-1 and ICAM-1 expression.	taraxasterol	0-12	vascular cell adhesion molecule 1	Homo sapiens	66-72
29951871-6	2018	Taraxasterol also suppressed LPS-induced NF-kappaB activation and VCAM-1 and ICAM-1 expression.	taraxasterol	0-12	intercellular adhesion molecule 1	Homo sapiens	77-83
29951871-7	2018	Furthermore, taraxasterol concentration-dependently increased the expression of LXRalpha.	taraxasterol	13-25	nuclear receptor subfamily 1 group H member 3	Homo sapiens	80-88
29951871-8	2018	The inhibition of taraxasterol on TNF-alpha, IL-8, PGE2, and NO production can be reversed by geranylgeranyl diphosphate (GGPP, the LXRalpha inhibitor).	taraxasterol	18-30	tumor necrosis factor	Homo sapiens	34-43
29951871-8	2018	The inhibition of taraxasterol on TNF-alpha, IL-8, PGE2, and NO production can be reversed by geranylgeranyl diphosphate (GGPP, the LXRalpha inhibitor).	taraxasterol	18-30	C-X-C motif chemokine ligand 8	Homo sapiens	45-49
29951871-8	2018	The inhibition of taraxasterol on TNF-alpha, IL-8, PGE2, and NO production can be reversed by geranylgeranyl diphosphate (GGPP, the LXRalpha inhibitor).	taraxasterol	18-30	nuclear receptor subfamily 1 group H member 3	Homo sapiens	132-140
29951871-9	2018	Here, we found that taraxasterol inhibited vascular inflammation through activating LXRalpha.	taraxasterol	20-32	nuclear receptor subfamily 1 group H member 3	Homo sapiens	84-92
30344887-0	2018	Protective Effects of Taraxasterol against Ethanol-Induced Liver Injury by Regulating CYP2E1/Nrf2/HO-1 and NF-kappaB Signaling Pathways in Mice.	taraxasterol	22-34	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	86-92
30344887-0	2018	Protective Effects of Taraxasterol against Ethanol-Induced Liver Injury by Regulating CYP2E1/Nrf2/HO-1 and NF-kappaB Signaling Pathways in Mice.	taraxasterol	22-34	nuclear factor, erythroid derived 2, like 2	Mus musculus	93-97
30344887-0	2018	Protective Effects of Taraxasterol against Ethanol-Induced Liver Injury by Regulating CYP2E1/Nrf2/HO-1 and NF-kappaB Signaling Pathways in Mice.	taraxasterol	22-34	heme oxygenase 1	Mus musculus	98-102
30344887-0	2018	Protective Effects of Taraxasterol against Ethanol-Induced Liver Injury by Regulating CYP2E1/Nrf2/HO-1 and NF-kappaB Signaling Pathways in Mice.	taraxasterol	22-34	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	107-116
30344887-10	2018	Taraxasterol significantly reduced the ethanol-induced increases of liver index, ALT, AST, and TG levels in sera and TG and MDA contents in the livers and hepatic ROS production and suppressed the ethanol-induced decreases of hepatic GSH level and SOD activity.	taraxasterol	0-12	glutamic pyruvic transaminase, soluble	Mus musculus	81-84
30344887-10	2018	Taraxasterol significantly reduced the ethanol-induced increases of liver index, ALT, AST, and TG levels in sera and TG and MDA contents in the livers and hepatic ROS production and suppressed the ethanol-induced decreases of hepatic GSH level and SOD activity.	taraxasterol	0-12	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	86-89
30344887-11	2018	Taraxasterol also significantly inhibited the secretion of proinflammatory cytokines TNF-alpha and IL-6 induced by ethanol.	taraxasterol	0-12	tumor necrosis factor	Mus musculus	85-94
30344887-11	2018	Taraxasterol also significantly inhibited the secretion of proinflammatory cytokines TNF-alpha and IL-6 induced by ethanol.	taraxasterol	0-12	interleukin 6	Mus musculus	99-103
30344887-13	2018	Further studies revealed that taraxasterol significantly inhibited the ethanol-induced upregulation of CYP2E1, increased the ethanol-induced downregulation of Nrf2 and HO-1, and inhibited the degradation of inhibitory kappa Balpha (IkappaBalpha) and the expression level of NF-kappaB p65 in liver tissues of ethanol-induced mice.	taraxasterol	30-42	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	103-109
30344887-13	2018	Further studies revealed that taraxasterol significantly inhibited the ethanol-induced upregulation of CYP2E1, increased the ethanol-induced downregulation of Nrf2 and HO-1, and inhibited the degradation of inhibitory kappa Balpha (IkappaBalpha) and the expression level of NF-kappaB p65 in liver tissues of ethanol-induced mice.	taraxasterol	30-42	nuclear factor, erythroid derived 2, like 2	Mus musculus	159-163
30344887-13	2018	Further studies revealed that taraxasterol significantly inhibited the ethanol-induced upregulation of CYP2E1, increased the ethanol-induced downregulation of Nrf2 and HO-1, and inhibited the degradation of inhibitory kappa Balpha (IkappaBalpha) and the expression level of NF-kappaB p65 in liver tissues of ethanol-induced mice.	taraxasterol	30-42	heme oxygenase 1	Mus musculus	168-172
30344887-13	2018	Further studies revealed that taraxasterol significantly inhibited the ethanol-induced upregulation of CYP2E1, increased the ethanol-induced downregulation of Nrf2 and HO-1, and inhibited the degradation of inhibitory kappa Balpha (IkappaBalpha) and the expression level of NF-kappaB p65 in liver tissues of ethanol-induced mice.	taraxasterol	30-42	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	232-244
30344887-13	2018	Further studies revealed that taraxasterol significantly inhibited the ethanol-induced upregulation of CYP2E1, increased the ethanol-induced downregulation of Nrf2 and HO-1, and inhibited the degradation of inhibitory kappa Balpha (IkappaBalpha) and the expression level of NF-kappaB p65 in liver tissues of ethanol-induced mice.	taraxasterol	30-42	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	274-283
30344887-13	2018	Further studies revealed that taraxasterol significantly inhibited the ethanol-induced upregulation of CYP2E1, increased the ethanol-induced downregulation of Nrf2 and HO-1, and inhibited the degradation of inhibitory kappa Balpha (IkappaBalpha) and the expression level of NF-kappaB p65 in liver tissues of ethanol-induced mice.	taraxasterol	30-42	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	284-287
29670526-5	2018	The effects of taraxasterol on LPS-induced TNF-alpha and IL-1beta production were detected by ELISA.	taraxasterol	15-27	tumor necrosis factor	Mus musculus	43-52
30344887-14	2018	These findings suggest that taraxasterol possesses the potential protective effects against ethanol-induced liver injury in mice by exerting antioxidative stress and anti-inflammatory response via CYP2E1/Nrf2/HO-1 and NF-kappaB signaling pathways.	taraxasterol	28-40	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	197-203
30344887-14	2018	These findings suggest that taraxasterol possesses the potential protective effects against ethanol-induced liver injury in mice by exerting antioxidative stress and anti-inflammatory response via CYP2E1/Nrf2/HO-1 and NF-kappaB signaling pathways.	taraxasterol	28-40	nuclear factor, erythroid derived 2, like 2	Mus musculus	204-208
30344887-14	2018	These findings suggest that taraxasterol possesses the potential protective effects against ethanol-induced liver injury in mice by exerting antioxidative stress and anti-inflammatory response via CYP2E1/Nrf2/HO-1 and NF-kappaB signaling pathways.	taraxasterol	28-40	heme oxygenase 1	Mus musculus	209-213
30344887-14	2018	These findings suggest that taraxasterol possesses the potential protective effects against ethanol-induced liver injury in mice by exerting antioxidative stress and anti-inflammatory response via CYP2E1/Nrf2/HO-1 and NF-kappaB signaling pathways.	taraxasterol	28-40	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	218-227
29806073-0	2018	Taraxasterol suppresses the growth of human liver cancer by upregulating Hint1 expression.	taraxasterol	0-12	histidine triad nucleotide binding protein 1	Homo sapiens	73-78
29806073-5	2018	Furthermore, Taraxasterol upregulated Hint1 and Bax, but downregulated Bcl2 and cyclin D1 expression, accompanied by promoting the demethylation in the Hint1 promoter region in liver cancer cells.	taraxasterol	13-25	histidine triad nucleotide binding protein 1	Homo sapiens	38-43
29806073-5	2018	Furthermore, Taraxasterol upregulated Hint1 and Bax, but downregulated Bcl2 and cyclin D1 expression, accompanied by promoting the demethylation in the Hint1 promoter region in liver cancer cells.	taraxasterol	13-25	BCL2 associated X, apoptosis regulator	Homo sapiens	48-51
29806073-5	2018	Furthermore, Taraxasterol upregulated Hint1 and Bax, but downregulated Bcl2 and cyclin D1 expression, accompanied by promoting the demethylation in the Hint1 promoter region in liver cancer cells.	taraxasterol	13-25	BCL2 apoptosis regulator	Homo sapiens	71-75
29806073-5	2018	Furthermore, Taraxasterol upregulated Hint1 and Bax, but downregulated Bcl2 and cyclin D1 expression, accompanied by promoting the demethylation in the Hint1 promoter region in liver cancer cells.	taraxasterol	13-25	cyclin D1	Homo sapiens	80-89
29806073-5	2018	Furthermore, Taraxasterol upregulated Hint1 and Bax, but downregulated Bcl2 and cyclin D1 expression, accompanied by promoting the demethylation in the Hint1 promoter region in liver cancer cells.	taraxasterol	13-25	histidine triad nucleotide binding protein 1	Homo sapiens	152-157
29806073-6	2018	The effects of Taraxasterol were abrogated by Hint1 silencing and partially mitigated by Bax silencing, Bcl2 or cyclin D1 over-expression in HepG2 cells.	taraxasterol	15-27	histidine triad nucleotide binding protein 1	Homo sapiens	46-51
29806073-6	2018	The effects of Taraxasterol were abrogated by Hint1 silencing and partially mitigated by Bax silencing, Bcl2 or cyclin D1 over-expression in HepG2 cells.	taraxasterol	15-27	BCL2 associated X, apoptosis regulator	Homo sapiens	89-92
29806073-6	2018	The effects of Taraxasterol were abrogated by Hint1 silencing and partially mitigated by Bax silencing, Bcl2 or cyclin D1 over-expression in HepG2 cells.	taraxasterol	15-27	BCL2 apoptosis regulator	Homo sapiens	104-108
29806073-6	2018	The effects of Taraxasterol were abrogated by Hint1 silencing and partially mitigated by Bax silencing, Bcl2 or cyclin D1 over-expression in HepG2 cells.	taraxasterol	15-27	cyclin D1	Homo sapiens	112-121
29806073-8	2018	Collectively, we demonstrate that Taraxasterol inhibits the growth of liver cancer at least partially by enhancing Hint1 expression to regulate Bax, Bcl2, and cyclin D1 expression.	taraxasterol	34-46	histidine triad nucleotide binding protein 1	Mus musculus	115-120
29806073-8	2018	Collectively, we demonstrate that Taraxasterol inhibits the growth of liver cancer at least partially by enhancing Hint1 expression to regulate Bax, Bcl2, and cyclin D1 expression.	taraxasterol	34-46	BCL2-associated X protein	Mus musculus	144-147
29806073-8	2018	Collectively, we demonstrate that Taraxasterol inhibits the growth of liver cancer at least partially by enhancing Hint1 expression to regulate Bax, Bcl2, and cyclin D1 expression.	taraxasterol	34-46	B cell leukemia/lymphoma 2	Mus musculus	149-153
29806073-8	2018	Collectively, we demonstrate that Taraxasterol inhibits the growth of liver cancer at least partially by enhancing Hint1 expression to regulate Bax, Bcl2, and cyclin D1 expression.	taraxasterol	34-46	cyclin D1	Mus musculus	159-168
29806073-11	2018	Taraxasterol enhances Hint1 expression by promoting demethylation in Hint1 promoter.	taraxasterol	0-12	histidine triad nucleotide binding protein 1	Homo sapiens	22-27
29806073-11	2018	Taraxasterol enhances Hint1 expression by promoting demethylation in Hint1 promoter.	taraxasterol	0-12	histidine triad nucleotide binding protein 1	Homo sapiens	69-74
29806073-12	2018	Taraxasterol increases Hint1 levels to regulate Bax, Bcl2, and cyclinD1 expression.	taraxasterol	0-12	histidine triad nucleotide binding protein 1	Homo sapiens	23-28
29806073-12	2018	Taraxasterol increases Hint1 levels to regulate Bax, Bcl2, and cyclinD1 expression.	taraxasterol	0-12	BCL2 associated X, apoptosis regulator	Homo sapiens	48-51
29806073-12	2018	Taraxasterol increases Hint1 levels to regulate Bax, Bcl2, and cyclinD1 expression.	taraxasterol	0-12	BCL2 apoptosis regulator	Homo sapiens	53-57
29806073-12	2018	Taraxasterol increases Hint1 levels to regulate Bax, Bcl2, and cyclinD1 expression.	taraxasterol	0-12	cyclin D1	Homo sapiens	63-71
29806073-13	2018	The effects of Taraxasterol are abrogated by Hint1 silencing in liver cancer cells.	taraxasterol	15-27	histidine triad nucleotide binding protein 1	Homo sapiens	45-50
29670526-5	2018	The effects of taraxasterol on LPS-induced TNF-alpha and IL-1beta production were detected by ELISA.	taraxasterol	15-27	interleukin 1 beta	Mus musculus	57-65
29670526-6	2018	The effects of taraxasterol on LXRalpha, ABCA1, TLR4, and NF-kappaB expression were detected by western blot analysis.	taraxasterol	15-27	nuclear receptor subfamily 1, group H, member 3	Mus musculus	31-39
29670526-6	2018	The effects of taraxasterol on LXRalpha, ABCA1, TLR4, and NF-kappaB expression were detected by western blot analysis.	taraxasterol	15-27	toll-like receptor 4	Mus musculus	48-52
29670526-6	2018	The effects of taraxasterol on LXRalpha, ABCA1, TLR4, and NF-kappaB expression were detected by western blot analysis.	taraxasterol	15-27	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	58-67
29670526-7	2018	The results showed that taraxasterol dose-dependently inhibited LPS-induced TNF-alpha and IL-1beta production and NF-kappaB activation.	taraxasterol	24-36	tumor necrosis factor	Mus musculus	76-85
29670526-7	2018	The results showed that taraxasterol dose-dependently inhibited LPS-induced TNF-alpha and IL-1beta production and NF-kappaB activation.	taraxasterol	24-36	interleukin 1 beta	Mus musculus	90-98
29670526-7	2018	The results showed that taraxasterol dose-dependently inhibited LPS-induced TNF-alpha and IL-1beta production and NF-kappaB activation.	taraxasterol	24-36	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	114-123
29670526-8	2018	Taraxasterol also disrupted the formation of lipid rafts and inhibited translocation of TLR4 into lipid rafts.	taraxasterol	0-12	toll-like receptor 4	Mus musculus	88-92
29670526-9	2018	Furthermore, taraxasterol was found to activate LXRalpha-ABCA1 signaling pathway which induces cholesterol efflux from cells.	taraxasterol	13-25	nuclear receptor subfamily 1, group H, member 3	Mus musculus	48-56
29670526-9	2018	Furthermore, taraxasterol was found to activate LXRalpha-ABCA1 signaling pathway which induces cholesterol efflux from cells.	taraxasterol	13-25	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	57-62
29670526-10	2018	In addition, our results showed that the anti-inflammatory effect of taraxasterol was attenuated by transfection with LXRalpha siRNA.	taraxasterol	69-81	nuclear receptor subfamily 1, group H, member 3	Mus musculus	118-126
29670526-11	2018	In conclusion, these results suggested that taraxasterol inhibits LPS-induced inflammatory response in BV2 microglia cells by activating LXRalpha-ABCA1 signaling pathway.	taraxasterol	44-56	nuclear receptor subfamily 1, group H, member 3	Mus musculus	137-145
29670526-11	2018	In conclusion, these results suggested that taraxasterol inhibits LPS-induced inflammatory response in BV2 microglia cells by activating LXRalpha-ABCA1 signaling pathway.	taraxasterol	44-56	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	146-151
28101182-6	2016	Furthermore, treatment with taraxasterol significantly suppressed tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6 and nuclear factor-kappaB protein expression levels compared with those in the rheumatoid arthritis model mice.	taraxasterol	28-40	tumor necrosis factor	Mus musculus	66-93
29670526-0	2018	Taraxasterol Inhibits LPS-Induced Inflammatory Response in BV2 Microglia Cells by Activating LXRalpha.	taraxasterol	0-12	nuclear receptor subfamily 1, group H, member 3	Mus musculus	93-101
28101182-6	2016	Furthermore, treatment with taraxasterol significantly suppressed tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6 and nuclear factor-kappaB protein expression levels compared with those in the rheumatoid arthritis model mice.	taraxasterol	28-40	interleukin 1 beta	Mus musculus	95-117
28101182-6	2016	Furthermore, treatment with taraxasterol significantly suppressed tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6 and nuclear factor-kappaB protein expression levels compared with those in the rheumatoid arthritis model mice.	taraxasterol	28-40	interleukin 6	Mus musculus	119-123
28101182-7	2016	Taraxasterol treatment also significantly reduced nitric oxide, prostaglandin E2 and cyclooxygenase-2 levels compared with those in the rheumatoid arthritis model group.	taraxasterol	0-12	prostaglandin-endoperoxide synthase 2	Mus musculus	85-101
27477353-0	2016	Taraxasterol inhibits cigarette smoke-induced lung inflammation by inhibiting reactive oxygen species-induced TLR4 trafficking to lipid rafts.	taraxasterol	0-12	toll-like receptor 4	Mus musculus	110-114
27477353-6	2016	The results showed that taraxasterol attenuated CS-induced lung pathological changes, inflammatory cells infiltration, inflammatory cytokines TNF-alpha, IL-6 and IL-1beta production.	taraxasterol	24-36	tumor necrosis factor	Mus musculus	142-151
27477353-6	2016	The results showed that taraxasterol attenuated CS-induced lung pathological changes, inflammatory cells infiltration, inflammatory cytokines TNF-alpha, IL-6 and IL-1beta production.	taraxasterol	24-36	interleukin 6	Mus musculus	153-157
27477353-6	2016	The results showed that taraxasterol attenuated CS-induced lung pathological changes, inflammatory cells infiltration, inflammatory cytokines TNF-alpha, IL-6 and IL-1beta production.	taraxasterol	24-36	interleukin 1 beta	Mus musculus	162-170
27477353-8	2016	In vitro, taraxasterol was found to inhibit CS-induced reactive oxygen species production, recruitment of TLR4 into lipid rafts, NF-kappaB activation, and IL-8 production.	taraxasterol	10-22	toll-like receptor 4	Mus musculus	106-110
27477353-8	2016	In vitro, taraxasterol was found to inhibit CS-induced reactive oxygen species production, recruitment of TLR4 into lipid rafts, NF-kappaB activation, and IL-8 production.	taraxasterol	10-22	chemokine (C-X-C motif) ligand 15	Mus musculus	155-159
25797286-0	2015	Taraxasterol inhibits IL-1beta-induced inflammatory response in human osteoarthritic chondrocytes.	taraxasterol	0-12	interleukin 1 beta	Homo sapiens	22-30
27109342-8	2016	Furthermore, taraxasterol significantly inhibited the overproduction of serum TNF-alpha, IL-1beta, PGE2 and RANKL, and increased serum OPG production in FCA-induced rats.	taraxasterol	13-25	tumor necrosis factor	Rattus norvegicus	78-87
27109342-8	2016	Furthermore, taraxasterol significantly inhibited the overproduction of serum TNF-alpha, IL-1beta, PGE2 and RANKL, and increased serum OPG production in FCA-induced rats.	taraxasterol	13-25	interleukin 1 beta	Rattus norvegicus	89-97
27109342-8	2016	Furthermore, taraxasterol significantly inhibited the overproduction of serum TNF-alpha, IL-1beta, PGE2 and RANKL, and increased serum OPG production in FCA-induced rats.	taraxasterol	13-25	TNF superfamily member 11	Rattus norvegicus	108-113
27109342-8	2016	Furthermore, taraxasterol significantly inhibited the overproduction of serum TNF-alpha, IL-1beta, PGE2 and RANKL, and increased serum OPG production in FCA-induced rats.	taraxasterol	13-25	TNF receptor superfamily member 11B	Rattus norvegicus	135-138
26622474-5	2015	This effect was accompanied by significantly decreased expression of vascular cell adhesion molecule 1 (VCAM-1) and cluster of differentiation (CD)80 for taraxasterol and that of CD80 for quercetin.	taraxasterol	154-166	vascular cell adhesion molecule 1	Homo sapiens	69-102
26622474-5	2015	This effect was accompanied by significantly decreased expression of vascular cell adhesion molecule 1 (VCAM-1) and cluster of differentiation (CD)80 for taraxasterol and that of CD80 for quercetin.	taraxasterol	154-166	vascular cell adhesion molecule 1	Homo sapiens	104-110
26622474-6	2015	In conclusion, the present study showed the protective effects of quercetin and taraxasterol against cell injury and inflammation in HUVECs and indicated that the effects were mediated via the downregulation of VCAM-1 and CD80 expression.	taraxasterol	80-92	vascular cell adhesion molecule 1	Homo sapiens	211-217
26622474-6	2015	In conclusion, the present study showed the protective effects of quercetin and taraxasterol against cell injury and inflammation in HUVECs and indicated that the effects were mediated via the downregulation of VCAM-1 and CD80 expression.	taraxasterol	80-92	CD80 molecule	Homo sapiens	222-226
25797286-4	2015	In order to provide a scientific basis for the applicability of taraxasterol in OA, the anti-inflammatory effects of taraxasterol on IL-1beta-stimulated osteoarthritic chondrocytes were investigated.	taraxasterol	117-129	interleukin 1 beta	Homo sapiens	133-141
25797286-8	2015	Our results demonstrated that taraxasterol dose-dependently suppressed MMP-1, MMP3, MMP13, PGE2 and NO production induced by IL-1beta.	taraxasterol	30-42	matrix metallopeptidase 1	Homo sapiens	71-76
25797286-8	2015	Our results demonstrated that taraxasterol dose-dependently suppressed MMP-1, MMP3, MMP13, PGE2 and NO production induced by IL-1beta.	taraxasterol	30-42	matrix metallopeptidase 3	Homo sapiens	78-82
25797286-8	2015	Our results demonstrated that taraxasterol dose-dependently suppressed MMP-1, MMP3, MMP13, PGE2 and NO production induced by IL-1beta.	taraxasterol	30-42	matrix metallopeptidase 13	Homo sapiens	84-89
25797286-8	2015	Our results demonstrated that taraxasterol dose-dependently suppressed MMP-1, MMP3, MMP13, PGE2 and NO production induced by IL-1beta.	taraxasterol	30-42	interleukin 1 beta	Homo sapiens	125-133
25797286-9	2015	The expression of COX-2 and iNOS was also inhibited by taraxasterol.	taraxasterol	55-67	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	18-23
25797286-9	2015	The expression of COX-2 and iNOS was also inhibited by taraxasterol.	taraxasterol	55-67	inositol-3-phosphate synthase 1	Homo sapiens	28-32
25797286-10	2015	Western blot analysis showed that taraxasterol suppressed IL-1beta-induced NF-kappaB activation in a dose-dependent manner.	taraxasterol	34-46	interleukin 1 beta	Homo sapiens	58-66
25797286-10	2015	Western blot analysis showed that taraxasterol suppressed IL-1beta-induced NF-kappaB activation in a dose-dependent manner.	taraxasterol	34-46	nuclear factor kappa B subunit 1	Homo sapiens	75-84
25797286-11	2015	Taken together, we found that taraxasterol protected human chondrocytes by inhibiting MMPs, NO and PGE2 production.	taraxasterol	30-42	matrix metallopeptidase 1	Homo sapiens	86-90
24286370-7	2014	Further studies revealed that taraxasterol significantly reduced TNF-alpha, IFN-gamma, IL-1beta, IL-6, NO and PGE2 levels in sera from mice with endotoxic shock.	taraxasterol	30-42	tumor necrosis factor	Mus musculus	65-74
24945401-0	2014	Effects of taraxasterol on iNOS and COX-2 expression in LPS-induced RAW 264.7 macrophages.	taraxasterol	11-23	nitric oxide synthase 2, inducible	Mus musculus	27-31
24945401-0	2014	Effects of taraxasterol on iNOS and COX-2 expression in LPS-induced RAW 264.7 macrophages.	taraxasterol	11-23	prostaglandin-endoperoxide synthase 2	Mus musculus	36-41
24945401-3	2014	To elucidate the underlying mechanism responsible for these effects, in the present study, we investigated the effects of taraxasterol on inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) expression, and mitogen-activated protein kinases (MAPKs) signaling pathway in LPS-induced RAW 264.7 macrophages.	taraxasterol	122-134	nitric oxide synthase 2, inducible	Mus musculus	138-169
24945401-3	2014	To elucidate the underlying mechanism responsible for these effects, in the present study, we investigated the effects of taraxasterol on inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) expression, and mitogen-activated protein kinases (MAPKs) signaling pathway in LPS-induced RAW 264.7 macrophages.	taraxasterol	122-134	nitric oxide synthase 2, inducible	Mus musculus	171-175
24945401-7	2014	RESULTS: The mRNA and protein expression levels of iNOS and COX-2 were inhibited by taraxasterol in a concentration-dependent manner.	taraxasterol	84-96	nitric oxide synthase 2, inducible	Mus musculus	51-55
24945401-7	2014	RESULTS: The mRNA and protein expression levels of iNOS and COX-2 were inhibited by taraxasterol in a concentration-dependent manner.	taraxasterol	84-96	prostaglandin-endoperoxide synthase 2	Mus musculus	60-65
24945401-8	2014	Further studies revealed that taraxasterol suppressed the phosphorylation of ERK1/2 and p38 in LPS-induced RAW 264.7 macrophages.	taraxasterol	30-42	mitogen-activated protein kinase 3	Mus musculus	77-83
24945401-8	2014	Further studies revealed that taraxasterol suppressed the phosphorylation of ERK1/2 and p38 in LPS-induced RAW 264.7 macrophages.	taraxasterol	30-42	mitogen-activated protein kinase 14	Mus musculus	88-91
24945401-9	2014	CONCLUSIONS: These results indicate that taraxasterol inhibits iNOS and COX-2 expression by blocking ERK1/2 and p38 MAPKs signaling pathway.	taraxasterol	41-53	nitric oxide synthase 2, inducible	Mus musculus	63-67
24945401-9	2014	CONCLUSIONS: These results indicate that taraxasterol inhibits iNOS and COX-2 expression by blocking ERK1/2 and p38 MAPKs signaling pathway.	taraxasterol	41-53	prostaglandin-endoperoxide synthase 2	Mus musculus	72-77
24945401-9	2014	CONCLUSIONS: These results indicate that taraxasterol inhibits iNOS and COX-2 expression by blocking ERK1/2 and p38 MAPKs signaling pathway.	taraxasterol	41-53	mitogen-activated protein kinase 3	Mus musculus	101-107
24945401-9	2014	CONCLUSIONS: These results indicate that taraxasterol inhibits iNOS and COX-2 expression by blocking ERK1/2 and p38 MAPKs signaling pathway.	taraxasterol	41-53	mitogen-activated protein kinase 14	Mus musculus	112-115
24548765-8	2014	The results showed that taraxasterol attenuated the infiltration of inflammatory cells, the activity of myeloperoxidase (MPO), lung wet/dry ratio, and the expression of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and interleukin-1beta (IL-1beta) in a dose-dependent manner.	taraxasterol	24-36	myeloperoxidase	Mus musculus	104-119
24548765-8	2014	The results showed that taraxasterol attenuated the infiltration of inflammatory cells, the activity of myeloperoxidase (MPO), lung wet/dry ratio, and the expression of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and interleukin-1beta (IL-1beta) in a dose-dependent manner.	taraxasterol	24-36	myeloperoxidase	Mus musculus	121-124
24548765-8	2014	The results showed that taraxasterol attenuated the infiltration of inflammatory cells, the activity of myeloperoxidase (MPO), lung wet/dry ratio, and the expression of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and interleukin-1beta (IL-1beta) in a dose-dependent manner.	taraxasterol	24-36	tumor necrosis factor	Mus musculus	169-196
24548765-8	2014	The results showed that taraxasterol attenuated the infiltration of inflammatory cells, the activity of myeloperoxidase (MPO), lung wet/dry ratio, and the expression of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and interleukin-1beta (IL-1beta) in a dose-dependent manner.	taraxasterol	24-36	tumor necrosis factor	Mus musculus	198-207
24548765-8	2014	The results showed that taraxasterol attenuated the infiltration of inflammatory cells, the activity of myeloperoxidase (MPO), lung wet/dry ratio, and the expression of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and interleukin-1beta (IL-1beta) in a dose-dependent manner.	taraxasterol	24-36	interleukin 6	Mus musculus	210-223
24548765-8	2014	The results showed that taraxasterol attenuated the infiltration of inflammatory cells, the activity of myeloperoxidase (MPO), lung wet/dry ratio, and the expression of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and interleukin-1beta (IL-1beta) in a dose-dependent manner.	taraxasterol	24-36	interleukin 6	Mus musculus	225-229
24548765-8	2014	The results showed that taraxasterol attenuated the infiltration of inflammatory cells, the activity of myeloperoxidase (MPO), lung wet/dry ratio, and the expression of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and interleukin-1beta (IL-1beta) in a dose-dependent manner.	taraxasterol	24-36	interleukin 1 beta	Mus musculus	235-252
24548765-8	2014	The results showed that taraxasterol attenuated the infiltration of inflammatory cells, the activity of myeloperoxidase (MPO), lung wet/dry ratio, and the expression of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and interleukin-1beta (IL-1beta) in a dose-dependent manner.	taraxasterol	24-36	interleukin 1 beta	Mus musculus	254-262
24548765-9	2014	Additionally, western blotting results showed that taraxasterol inhibited the phosphorylation of IkappaB-alpha, p65 NF-kappaB, p46-p54 JNK, p42-p44 ERK, and p38 caused by LPS.	taraxasterol	51-63	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	97-110
24548765-9	2014	Additionally, western blotting results showed that taraxasterol inhibited the phosphorylation of IkappaB-alpha, p65 NF-kappaB, p46-p54 JNK, p42-p44 ERK, and p38 caused by LPS.	taraxasterol	51-63	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	112-125
24548765-9	2014	Additionally, western blotting results showed that taraxasterol inhibited the phosphorylation of IkappaB-alpha, p65 NF-kappaB, p46-p54 JNK, p42-p44 ERK, and p38 caused by LPS.	taraxasterol	51-63	mitogen-activated protein kinase 14	Mus musculus	157-160
24286370-7	2014	Further studies revealed that taraxasterol significantly reduced TNF-alpha, IFN-gamma, IL-1beta, IL-6, NO and PGE2 levels in sera from mice with endotoxic shock.	taraxasterol	30-42	interferon gamma	Mus musculus	76-85
24286370-7	2014	Further studies revealed that taraxasterol significantly reduced TNF-alpha, IFN-gamma, IL-1beta, IL-6, NO and PGE2 levels in sera from mice with endotoxic shock.	taraxasterol	30-42	interleukin 1 beta	Mus musculus	87-95
24286370-7	2014	Further studies revealed that taraxasterol significantly reduced TNF-alpha, IFN-gamma, IL-1beta, IL-6, NO and PGE2 levels in sera from mice with endotoxic shock.	taraxasterol	30-42	interleukin 6	Mus musculus	97-101
23727181-0	2013	Effects of taraxasterol on ovalbumin-induced allergic asthma in mice.	taraxasterol	11-23	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	27-36
23727181-2	2013	In the present study, we determined the in vivo protective effect of taraxasterol on allergic asthma induced by ovalbumin (OVA) in mice.	taraxasterol	69-81	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	112-121
23727181-8	2013	RESULTS: Taraxasterol dramatically decreased the total inflammatory cell and main inflammatory cell counts, reduced the production of Th2 cytokine IL-4, IL-5, IL-13 in BALF and OVA-specific IgE in sera, and suppressed AHR in a dose-dependent manner.	taraxasterol	9-21	heart and neural crest derivatives expressed 2	Mus musculus	134-137
23727181-8	2013	RESULTS: Taraxasterol dramatically decreased the total inflammatory cell and main inflammatory cell counts, reduced the production of Th2 cytokine IL-4, IL-5, IL-13 in BALF and OVA-specific IgE in sera, and suppressed AHR in a dose-dependent manner.	taraxasterol	9-21	interleukin 4	Mus musculus	147-151
23727181-8	2013	RESULTS: Taraxasterol dramatically decreased the total inflammatory cell and main inflammatory cell counts, reduced the production of Th2 cytokine IL-4, IL-5, IL-13 in BALF and OVA-specific IgE in sera, and suppressed AHR in a dose-dependent manner.	taraxasterol	9-21	interleukin 5	Mus musculus	153-157
23727181-8	2013	RESULTS: Taraxasterol dramatically decreased the total inflammatory cell and main inflammatory cell counts, reduced the production of Th2 cytokine IL-4, IL-5, IL-13 in BALF and OVA-specific IgE in sera, and suppressed AHR in a dose-dependent manner.	taraxasterol	9-21	interleukin 13	Mus musculus	159-164
34848154-0	2022	Taraxasterol mitigates Con A-induced hepatitis in mice by suppressing interleukin-2 expression and its signaling in T lymphocytes.	taraxasterol	0-12	interleukin 2	Mus musculus	70-83
22366673-6	2012	RESULTS: We found that taraxasterol inhibited NO, PGE(2), TNF-alpha, IL-1beta and IL-6 production in LPS-induced RAW 264.7 macrophages in a dose-dependent manner.	taraxasterol	23-35	tumor necrosis factor	Mus musculus	58-67
22366673-6	2012	RESULTS: We found that taraxasterol inhibited NO, PGE(2), TNF-alpha, IL-1beta and IL-6 production in LPS-induced RAW 264.7 macrophages in a dose-dependent manner.	taraxasterol	23-35	interleukin 1 beta	Mus musculus	69-77
22366673-6	2012	RESULTS: We found that taraxasterol inhibited NO, PGE(2), TNF-alpha, IL-1beta and IL-6 production in LPS-induced RAW 264.7 macrophages in a dose-dependent manner.	taraxasterol	23-35	interleukin 6	Mus musculus	82-86
22366673-7	2012	Further studies revealed that taraxasterol prevented the LPS-induced NF-kappaB translocation from cytoplasm into nuclear.	taraxasterol	30-42	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	69-78
22366673-8	2012	CONCLUSIONS: These results indicate that taraxasterol has anti-inflammatory effect by blocking NF-kappaB pathway.	taraxasterol	41-53	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	95-104
33794459-6	2021	For Mpro were, in kcal/mol: -9.36 for spirostan, -8.75 for N-(3-acetylglycyrrhetinoyl)-2-amino-propanol, -8.41 for alpha-amyrin, -8.35 for oleanane, -8.11 for taraxasterol, and -8.03 for glycyrrhetinic acid.	taraxasterol	159-171	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	4-8
34848154-5	2022	Our results showed that TAS significantly suppressed Con A-induced acute hepatitis in a mouse model, reducing the hepatic necrosis areas, the release of aminotransferases, and the production of IL-2 and other inflammatory cytokines.	taraxasterol	24-27	interleukin 2	Mus musculus	194-198
34848154-6	2022	Supporting this, in vitro study also showed that TAS reduced the production of IL-2 and the expression of IL-2 receptor subunit alpha (CD25) upon the stimulation of Con A, which was likely mediated by suppressing NF-kappaB activation.	taraxasterol	49-52	interleukin 2	Mus musculus	79-83
34848154-6	2022	Supporting this, in vitro study also showed that TAS reduced the production of IL-2 and the expression of IL-2 receptor subunit alpha (CD25) upon the stimulation of Con A, which was likely mediated by suppressing NF-kappaB activation.	taraxasterol	49-52	interleukin 2 receptor, alpha chain	Mus musculus	106-133
34848154-6	2022	Supporting this, in vitro study also showed that TAS reduced the production of IL-2 and the expression of IL-2 receptor subunit alpha (CD25) upon the stimulation of Con A, which was likely mediated by suppressing NF-kappaB activation.	taraxasterol	49-52	interleukin 2 receptor, alpha chain	Mus musculus	135-139
34848154-6	2022	Supporting this, in vitro study also showed that TAS reduced the production of IL-2 and the expression of IL-2 receptor subunit alpha (CD25) upon the stimulation of Con A, which was likely mediated by suppressing NF-kappaB activation.	taraxasterol	49-52	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	213-222
34848154-9	2022	Our data indicate that TAS can suppress both T lymphocyte activation and cell proliferation by down-regulating IL-2 expression and its signaling pathway thereby ameliorating Con A-induced acute hepatitis, highlighting TAS as a potential drug candidate for treating inflammatory diseases including autoimmune hepatitis.	taraxasterol	23-26	interleukin 2	Mus musculus	111-115
34848154-9	2022	Our data indicate that TAS can suppress both T lymphocyte activation and cell proliferation by down-regulating IL-2 expression and its signaling pathway thereby ameliorating Con A-induced acute hepatitis, highlighting TAS as a potential drug candidate for treating inflammatory diseases including autoimmune hepatitis.	taraxasterol	218-221	interleukin 2	Mus musculus	111-115
34776631-0	2021	Taraxasterol suppresses cell proliferation and boosts cell apoptosis via inhibiting GPD2-mediated glycolysis in gastric cancer.	taraxasterol	0-12	glycerol-3-phosphate dehydrogenase 2	Homo sapiens	84-88
34776631-10	2021	Furthermore, overexpression of GPD2 reversed the inhibitory effects of TAX on the proliferative and clone-forming abilities of GC cells as well as abolished the promoting effects of TAX on the apoptosis of GC cells.	taraxasterol	71-74	glycerol-3-phosphate dehydrogenase 2	Homo sapiens	31-35
34776631-10	2021	Furthermore, overexpression of GPD2 reversed the inhibitory effects of TAX on the proliferative and clone-forming abilities of GC cells as well as abolished the promoting effects of TAX on the apoptosis of GC cells.	taraxasterol	182-185	glycerol-3-phosphate dehydrogenase 2	Homo sapiens	31-35
35128947-0	2022	Taraxasterol attenuates melanoma progression via inactivation of reactive oxygen species-mediated PI3K/Akt signaling pathway.	taraxasterol	0-12	AKT serine/threonine kinase 1	Homo sapiens	103-106